🎙️ María José Soler Romeo comparte la visión europea sobre la protección renal en diabetes tipo 2 en #ISNWCN 🇯🇵
👉 Entrevista disponible en el canal de
YouTube de @isnkidneycare.bsky.social: “Kidney protection in type 2 diabetes: A Western European perspective”
🔗 youtube.com/watch?v=EwL2...
At #ISNWCN, we spoke with Lilian Kaplan Prize winner Prof. Ron Gansevoort.
“Be inspired. We are all clinicians. That's our basic task.”
He encourages young nephrologists to pursue research while staying grounded in clinical care.
🎥 bit.ly/3PU8aN3 @pkdfoundation.bsky.social
So much more to say, but I will end this thread with the regret that my X account was hacked. Even X has not been the same lately; for so much time being there, it feels like someone stole some of my identity.
For now, please don't interact with any message you receive from my account #ISNWCN
14/ Last but not least- jet-lagged night walks, sharing a Pikachu 🍫, and drawing omikuji paper fortunes at a Buddhist temple. Small moments turning into memories, that keep us close long after the meeting ends #ISNWCN @drbarbateba.bsky.social @arunkumarnephro.bsky.social @hswapnil.medsky.social
12/ Meeting for the first time in person, while we were in the same #NSMC cohort (almost 4 years ago) #ISNWCN
11/ 😍Reconnecting with old friends #ISNWCN
@dakidneydoc.bsky.social @drbarbateba.bsky.social @drsumanbehera.bsky.social @arunkumarnephro.bsky.social
10/ One of the charms of #ISNWCN was randomly bumping into so many inspiring persons.
* I still didn't found all the pictures fitting into this chaper
@rosertorra.bsky.social @priti899.bsky.social
9/ Not quite myself for a bit at ISN - even arrived very late to the Emerging Leaders program. Still grateful to be there, inspired by the previous generation, generous mentors, and my Cohort 4 colleagues. #ISNWCN
8/ Divya Bajpai and I were minutes from getting locked in a conference room at 10:30 pm the night before, while working on our presentation #ISNWCN
🌞The next day: our spotlight session on senior vs junior perspectives on social media in clinical practice and education
7/ Participated in Kidney Tank. I’ll let you guess the hour; I'll just say we won. Tough brief, time crunch, tech issues, and jet lag, so we leaned on creativity and each other. Learned a lot about where social media in nephrology is heading #ISNWCN @theisn.org
6/ Second time meeting in person- and still thinking how much I’ve learned from @lastwalsh.bsky.social over the past nine months through the RADIANT program. Grateful for the guidance and the perspective #ISNWCN
5/ #NephJC covering all the simultaneous LBCT publications was a stretch- even beyond the jet lag. Teamwork made it possible. The goal stayed simple: bring those at home closer and make them part of the #ISNWCN vibe
@hswapnil.medsky.social @brianrifkin.bsky.social
www.nephjc.com/news/isnwcn-...
4/ Live-covering late-breaking clinical trials with one of the OGs. And in between, the kind of thoughtful conversations where he quietly points out what I would have otherwise missed #ISNWCN
2/ Being part of the #ISNWCN social media team was energizing. Meeting some people for the first time, reconnecting with others I already knew, and learning throughout, it made me appreciate our community even more. Grateful to help amplify it
35 hours of travel to reach #ISNWCN, and every second was worth it. Standing here, surrounded by colleagues and friends from across the world, the only feeling is privilege - grateful to have made it, grateful to learn, grateful to share this space with a global kidney community
✨My short recap
🏃♀️🌏 Moving for better health.
This #WorldPhysicalActivityDay, ISN reflects on #WorldKidneyDay's 5K Run in Yokohama during #ISNWCN.
For people with kidney disease, physical activity helps manage blood pressure, support heart health, and improve wellbeing.
Every step counts.
#KidneyHealthMatters
Discover the recordings of the industry symposia from WCN’26. These sessions highlight the latest advancements in global kidney care. The recordings are now available open access on the ISN Academy: https://academy.theisn.org/wcn26 #ISNWCN
Do you have #FOMO from missing all the fun at #ISNWCN ?
We've got you covered!!
Check out the interview with
@nephroseeker.medsky.social and @hswapnil.medsky.social
discussing simultaneous publications at WCN in Yokohama, Japan #NephSky
www.nephjc.com/news/conf-coverage
Grateful to have been part of #ISNWCN in 🇯🇵. Inspiring to connect with a global kidney community and witness the exchange of science, practice, and patient voices. Social media helped extend these conversations worldwide. Leaving energized and committed to better kidney care for all.
Spoke with the HCP Live folks about the WHO lead HEARTS program for BP control, based on the talk at #ISNWCN
see it here
Thank you for making #ISNWCN unforgettable.
From Yokohama to around the world, your engagement brought the kidney community together to share science and drive progress in kidney care.
We look forward to welcoming you to the next congress.
The #NephJC crew cover the simultaneous publications from the #ISNWCN www.nephjc.com/news/isnwcn-...
Iptacopan IN NEJM
Atrasentan with Flozin in JASN
Age/Sex interactions from CONFIDENCE in NDT
Mediation analysis from CONFIDENCE also in JASN
Covering the world 🌐 @hswapnil.medsky.social @nephroseeker.medsky.social
🧑💻Reporting in from Yokohama, Japan #ISNWCN 🌸
📰Read all about the late breaking news #NephJC #NephSky
www.nephjc.com/news/isnwcn-yokohama
The International Society of Nephrology General Assembly is currently taking place in Yokohama during World Congress of Nephrology 2026.
Members are gathering to discuss ongoing work and next steps for the organization.
#ISNWCN #ThisIsISN
Did you know that the “four-hit” hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/21949093/
Take-home from WCN26:
IgAN treatment is shifting from nonspecific immunosuppression to pathway-directed therapy.
The debate is no longer whether to treat, but where in the pathway to intervene first. 🧵 (10)
#GlomerularDisease
#ISNWCN
Future IgAN management may involve combination or sequential therapy:
• Gut-targeted immunomodulation
• Complement inhibition
• Possibly BAFF/APRIL blockade
Precision treatment for a heterogeneous disease. 🧵 (9)
#GlomerularDisease
#ISNWCN
🔑 clinical question:
Should therapy first target the cause of IgAN
or the mechanism of kidney injury?
This remains unresolved and likely depends on patient phenotype. 🧵(8)
#GlomerularDisease
#ISNWCN
However, mechanisms differ.
Nefecon → modifies disease origin (gut immune system)
Complement inhibitors → block final inflammatory pathway in kidney
Upstream control vs downstream protection. 🧵 (7)
#GlomerularDisease
#ISNWCN
